The Prognostic Value of the Prechemotherapy Neutrophil - Lymphocyte Ratio in Gastric Cancer

Monika Magdy Youssef;

Abstract


astric cancer is the fifth most common cancer worldwide, with about one million newly diagnosed cases annually.
It causes one of the highest cancer burdens, as measured by disability-adjusted life years lost. It is the third-leading cause of cancer-related death worldwide, after lung and liver malignancies.
It exhibits diverse prognoses according to various intrinsic characteristics. Therefore, the development of efficient treatment strategies for the various prognostic groups within GC is important.
It is increasingly recognised that variations within clinical outcomes in cancer patients are influenced by not only the oncological characteristics of the tumor, but also the host-response factors.
In our retrospective study, we focused on the prechemotherapy neutrophil-to-lymphocyte ratio (NLR) as a marker of both tumor microenviroment and systemic inflammation.
The study included 61 patients; diagnosed with either Gastric or GEJ cancer and presented to Oncology Department, at Ain Shams University Hospital, from January 2013 till December 2016.
We collected all data about patients’


Other data

Title The Prognostic Value of the Prechemotherapy Neutrophil - Lymphocyte Ratio in Gastric Cancer
Other Titles دور نسبة الخلايا الحبيبية المتعادلة إلى الخلايا الليمفاوية ما قبل العلاج الكيماوي كنذير مرضي في مرض أورام المعدة
Authors Monika Magdy Youssef
Issue Date 2017

Attached Files

File SizeFormat
J5112.pdf278.05 kBAdobe PDFView/Open
Recommend this item

Similar Items from Core Recommender Database

Google ScholarTM

Check

downloads 1 in Shams Scholar


Items in Ain Shams Scholar are protected by copyright, with all rights reserved, unless otherwise indicated.